The endocannabinoid system as a target for therapeutic drugs

Trends in Pharmacological Sciences

Volumn 21, Issue 6, 2000, Pages 218-224

  Piomelli, Daniele ^a   Giuffrida, Andrea ^b   Calignano, Antonio ^b   Rodríguez De Fonseca, Fernando ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; GLUTAMATE RECEPTOR; L 759633; L 759656; LIPID; NEUROTRANSMITTER; PHOSPHOLIPID; RECEPTOR SUBTYPE; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

BRAIN ISCHEMIA; CELL MEMBRANE; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HYDROLYSIS; MOTOR DYSFUNCTION; NERVE CELL MEMBRANE; NEUROPATHY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; PSYCHOSIS; REGULATORY MECHANISM; REVIEW;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; POLYUNSATURATED ALKAMIDES; PSYCHOTROPIC DRUGS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0034212295     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01482-6     Document Type: Review

References (61)

1. 1 Devane, W.A. et al. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613
2. 2 Matsuda, L.A. et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564
3. 3 Devane, W. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949
4. 4 Sugiura, T. et al. (1995) 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97
5. 5 Mechoulam, R. et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90
6. 6 Piomelli, D. et al (1998) Endogenous cannabinoid signaling. Neurobiol. Dis. 5, 462-473
7. 7 Giuffrida, A. et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358-363
8. 8 Beltramo, M. et al (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097
9. 9 Piomelli, D. et al. (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. U. S. A. 96, 5802-5807
10. 10 Schmid, P.C. et al. (1985) Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem. 260, 14145-14149
11. 11 Cravatt, B.F. et al. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87
12. 12 Stella, N. et al. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778
13. 13 Mechoulam, R. et al (1998) Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur. J. Pharmacol. 362, R1-R3
14. 14 Goparaju, S.K. et al. (1999) Enzymes of porcine brain hydrolysing 2-arachidonylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol. 57, 417-423
15. 2-receptor responses by an anandamide transport inhibitor. J. Neurosci. 20, 3401-3407
16. 16 Calignano, A. et al. (1997) Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol. 337, R1-R2
17. 17 Gonzalez, S. et al. (1999) Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. 65, 327-336
18. 18 Khanolkar, A.D. and Makriyannis, A. (1999) Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sci. 65, 607-616
19. 19 Salamone, J. et al. (2000) 6th Internet World Congress for Biomedical Sciences (http://www.uclm.es/inabis2000/symposia/files/119/index.htm)
20. 20 Munro, S. et al. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65
21. 2 receptors. Pharmacol. Ther. 74, 129-180
22. 1 cannabinoid receptor mediate desensitization and internalization. J. Neurosci. 19, 3773-3780
23. 2 phosphorylation by the inverse agonist SR 144528. J. Biol. Chem. 274, 20397-20405
24. 24 Gifford, A.N. et al. (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J. Pharmacol. Exp. Ther. 288, 478-483
25. 25 Klein, T.W. et al. (1998) Cannabinoid receptors and immunity. Immunol. Today 19, 373-381
26. 2 receptors. Proc. Natl. Acad. Sci. U. S. A. 96, 14136-14141
27. 27 Zygmunt, P.M. et al. (2000) Anandamide - the other side of the coin. Trends Pharmacol. Sci. 21, 43-44
28. 28 Szolcsányi, J. (2000) Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol. Sci. 21, 41-42
29. 29 Joy, J.E. et al., eds (1999) Marijuana and Medicine: Assessing the Science Base, National Academy Press
30. 30 Martin, W.J. et al. (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 822, 237-242
31. 31 Hohmann, A.G. et al (1999) Pre-and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 822, 17-25
32. 1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90, 923-931
33. 33 Richardson, J.D. et al. (1998) Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18, 451-457
34. 34 Hohmann, A.G. and Herkenham, M. (1999) Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92, 1171-1175
35. 35 Calignano, A. et al. (1998) Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281
36. 1 receptors. Pain 75, 111-119
37. 37 Martin, B.R. and Lichtman, A.H. (1998) Cannabinoid transmission and pain perception. Neurobiol. Dis. 5, 447-461
38. 38 Hamann, W. and di Vadi, P.P. (1999) Analgesic effects of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 353, 560
39. 39 Herzberg, U. et al. (1997) The analgesic effects of R(1)-Win 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221, 157-160
40. 40 Li, J. et al. (1999) The cannabinoid receptor agonist WIN 55, 212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 81, 25-33
41. 41 Martin, W.J. et al. (1999) Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 82, 199-205
42. 42 Walker, J.M. et al. (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. U. S. A. 96, 12198-12203
43. 43 Stein, C. (1995) The control of pain in peripheral tissue by opioids. New Engl. J. Med. 332, 1685-1690
44. 44 Collins, D.R. et al. (1994) The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. Eur. J. Pharmacol. 259, R7-R8
45. 45 Lee, J.M. et al. (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399, A7-A14
46. 46 Shen, M. and Thayer, S.A. (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459-462
47. 47 Nagayama, T. et al. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995
48. 48 Sañudo-Peña, M.C. et al. (1998) Effects of intrastriatal cannabinoid on rotational behavior in rats: interactions with the dopaminergic system. Synapse 30, 221-226
49. 1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96, 5780-5785
50. 50 Brotchie, J.M. (1998) Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. 13, 871-876
51. 51 Müller-Vahl, K.R. et al. (1999) Treatment of Tourette-Syndrome with Δ-9-tetrahydrocannabinol. Am. J. Psychiatry 156, 495
52. 52 Andréasson, S. et al. (1987) Cannabis and schizophrenia. Lancet 2, 1483-1486
53. 53 Gorriti, M.A. et al. (1999) Chronic (-)-Δ9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur. J. Pharmacol. 365, 133-142
54. 54 Howlett, A.C. (1995) Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35, 607-633
55. 55 Abadji, U. et al. (1994) (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37, 1889-1893
56. 2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 989-999
57. 1). J. Pharmacol. Exp. Ther. 289, 1427-1433
58. 2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 12, 665-672
59. 2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U. S. A. 96, 14228-14233
60. 60 Rinaldi-Carmona, M. et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244
61. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650